Lifecore Biomedical
LFCR
95 hedge funds and large institutions have $206M invested in Lifecore Biomedical in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
36% more call options, than puts
Call options by funds: $15K | Put options by funds: $11K
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
8% more funds holding
Funds holding: 88 → 95 (+7)
1.08% less ownership
Funds ownership: 92.85% → 91.76% (-1.1%)
12% less capital invested
Capital invested by funds: $235M → $206M (-$29.2M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPAM
Legion Partners Asset Management
Los Angeles,
California
|
+$5.39M |
| 2 |
Morgan Stanley
New York
|
+$3.3M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$2.33M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.81M |
| 5 |
Renaissance Technologies
New York
|
+$854K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$10.7M |
| 2 |
WC
Walthausen & Co
Malta,
New York
|
-$2.98M |
| 3 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$2.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.94M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
101
Valeo Financial Advisors
Carmel,
Indiana
| – | -$20K | -2,000 | Closed |
|
102
Lazard Asset Management
New York
| – | -$7K | -879 | Closed |
|
|
PA
103
Parallel Advisors
San Francisco,
California
| – | +$1.01K | +98 | New |
|
LFCR Hedge Fund Activity: Q2 2020 in Review
95 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2020, worth a combined $206M — down 12% from $235M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LFCR positions and 9 closed out — a net gain of 7 holders — while 35 added to existing stakes and 26 trimmed.
The largest buyer was Legion Partners Asset Management, adding an estimated $5.39M. The largest seller was NWQ Investment Management Company, cutting an estimated $10.7M.
- 95 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2020, up from 88 in Q1 2020.
- Funds reported $206M of Lifecore Biomedical stock for Q2 2020, down 12% quarter-over-quarter.
- 16 funds opened new Lifecore Biomedical positions in Q2 2020 and 9 closed out, a net change of +7 holders.
- The largest Lifecore Biomedical buyer in Q2 2020 was Legion Partners Asset Management, an estimated $5.39M added.
- The largest Lifecore Biomedical seller in Q2 2020 was NWQ Investment Management Company, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2020.